Pulmonary Circulation最新文献_第9页

Tricuspid annular plane systolic excursion in pulmonary hypertension-Moving beyond the sector plane. 肺动脉高压的三尖瓣环平面收缩期偏移--超越扇形平面。

IF 2.2 4区医学

Pulmonary Circulation Pub Date : 2024-09-06 eCollection Date: 2024-07-01 DOI: 10.1002/pul2.12416

Kenzo Ichimura, Bettia E Celestin, Shadi P Bagherzadeh, Roham T Zamanian, Michael Salerno, Edda Spiekerkoetter, Francois Haddad

{"title":"Tricuspid annular plane systolic excursion in pulmonary hypertension-Moving beyond the sector plane.","authors":"Kenzo Ichimura, Bettia E Celestin, Shadi P Bagherzadeh, Roham T Zamanian, Michael Salerno, Edda Spiekerkoetter, Francois Haddad","doi":"10.1002/pul2.12416","DOIUrl":"10.1002/pul2.12416","url":null,"abstract":"Tricuspid annular plane systolic excursion (TAPSE) is usually measured with M-mode using sector line, however, this may not align with the anatomical shortening of the right ventricular (RV). In this study, we compared the different methods to measure TAPSE using three different reference lines (sector line, anatomical line, and apico-annular line). We included 148 patients diagnosed with pulmonary arterial hypertension (PAH) who underwent TTE and right heart catheterization within 2 weeks of each other. TAPSE was measured by M-mode (sector, anatomical), 2D (sector, anatomical), or as tricuspid apico-annular displacement (TAAD). Agreement between measures was assessed using coefficient of variation (COV), Spearman's correlation, and Bland-Altman analysis. Receiver-operating characteristics and Kaplan-Meier analysis were used to explore associations with the combined outcome of death or lung transplantation at 5 years. There was a good concordance between anatomical and sector M-mode with a COV of 15.5 ± 1.6% and a bias of -0.6 ± 3.2 mm. In contrast, anatomical M-mode TAPSE and TAAD differed significantly with the mean difference of 3.3 ± 3.8 mm (COV 30.5 ± 6.1%; p < 0.0001). Among the different 2D methods, anatomical 2D agreed well with anatomical M-mode TAPSE (COV of 11.8 ± 2.0%; r = 0.89; p < 0.0001). Among the five methods, TADD had the strongest association with the combined endpoint of death or transplantation at 5 years (C-statistic 0.64, 95% confidence interval [CI] 0.57-0.71). We concluded that different measures of TAPSE are not interchangeable.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"14 3","pages":"e12416"},"PeriodicalIF":2.2,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Balloon pulmonary angioplasty for proximal chronic thromboembolic pulmonary hypertension in patients ineligible for pulmonary endarterectomy. 球囊肺血管成形术治疗不符合肺动脉内膜切除术条件的近端慢性血栓栓塞性肺动脉高压。

IF 2.2 4区医学

Pulmonary Circulation Pub Date : 2024-09-03 eCollection Date: 2024-07-01 DOI: 10.1002/pul2.12432

Justin Issard, Elie Fadel, Samuel Dolidon, Benoit Gerardin, Dominique Fabre, Delphine Mitilian, Olaf Mercier, Mitja Jevnikar, Xavier Jais, Marc Humbert, Philippe Brenot

{"title":"Balloon pulmonary angioplasty for proximal chronic thromboembolic pulmonary hypertension in patients ineligible for pulmonary endarterectomy.","authors":"Justin Issard, Elie Fadel, Samuel Dolidon, Benoit Gerardin, Dominique Fabre, Delphine Mitilian, Olaf Mercier, Mitja Jevnikar, Xavier Jais, Marc Humbert, Philippe Brenot","doi":"10.1002/pul2.12432","DOIUrl":"10.1002/pul2.12432","url":null,"abstract":"Balloon pulmonary angioplasty (BPA) to treat chronic thromboembolic pulmonary hypertension (CTEPH) is generally reserved for distal obstruction precluding pulmonary endarterectomy (PEA) but can be used in patients with proximal disease who are at high surgical risk or refuse surgery. This single-center retrospective study compared BPA efficacy in patients with proximal versus distal CTEPH. Of the 478 patients, 36 had proximal disease, follow-up was 11.6 months and mean number of BPA 6. After BPA, PVR, and mean pulmonary artery pressure decreased significantly in the proximal and distal groups (from 6.5 to 4.0 WU and 39 to 31 mmHg and from 7.6 to 3.8 WU and 44 to 31 mmHg, respectively, p < 0.001 for all comparisons). NYHA class also improved significantly in both groups, from 3 to 2, whereas the 6-min walk distance, cardiac output, and serum NT pro-BNP showed significant improvements only in the distal group. Thus, when PEA for CTEPH is technically feasible but not performed due to severe comorbidities or patient refusal, BPA can produce significant hemodynamic improvements, albeit less marked than in patients with distal disease. Better patient selection to BPA might improve outcomes in patients with proximal disease who are ineligible for PEA.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"14 3","pages":"e12432"},"PeriodicalIF":2.2,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension. 联合化疗和免疫疗法可改善肺动脉高压。

IF 2.2 4区医学

Pulmonary Circulation Pub Date : 2024-09-02 eCollection Date: 2024-07-01 DOI: 10.1002/pul2.12426

Tejaswini P Reddy, Roberto Barrios, Eric Bernicker, Wei Qian, Jenny Chang, Zeenat Safdar

{"title":"Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension.","authors":"Tejaswini P Reddy, Roberto Barrios, Eric Bernicker, Wei Qian, Jenny Chang, Zeenat Safdar","doi":"10.1002/pul2.12426","DOIUrl":"10.1002/pul2.12426","url":null,"abstract":"Treatment modalities for pulmonary arterial hypertension (PAH) improve quality of life and walk distance. However, none of these therapies alter the structural/functional pulmonary vascular integrity that results in vascular remodeling. PAH smooth muscle cells share biological characteristics with cancer cells, which may be potential therapeutic targets for PAH. We present a case of a patient with connective tissue disease (CTD)-associated PAH treated on triple therapy who developed metastatic lung adenocarcinoma. While on PAH triple-therapy, she received a combination of carboplatin, pemetrexed, and pembrolizumab. She eventually had a complete pathologic response, no evidence of cancer recurrence, and significant improvement of PAH/overall clinical status. After discontinuation of neoplastic therapy, her clinical status worsened, she eventually passed away, and lung biopsy findings revealed evidence of severe pulmonary smooth muscle cell hypertrophy and pulmonary veno-occlusive disease. This report suggests that combined chemotherapy and immunotherapy may influence the efficacy of PAH therapies and improve clinical status.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"14 3","pages":"e12426"},"PeriodicalIF":2.2,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11366960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulmonary perfusion in long-term survivors of COVID-19-related severe acute respiratory distress syndrome treated by extracorporeal membrane oxygenation. 通过体外膜氧合治疗 COVID-19 相关严重急性呼吸窘迫综合征长期存活者的肺灌注。

IF 2.2 4区医学

Pulmonary Circulation Pub Date : 2024-08-25 eCollection Date: 2024-07-01 DOI: 10.1002/pul2.12431

Lucie Miksová, Vladimír Dytrych, Václav Ptáčník, Martin Balík, Aleš Linhart, Jan Bělohlávek, Pavel Jansa

{"title":"Pulmonary perfusion in long-term survivors of COVID-19-related severe acute respiratory distress syndrome treated by extracorporeal membrane oxygenation.","authors":"Lucie Miksová, Vladimír Dytrych, Václav Ptáčník, Martin Balík, Aleš Linhart, Jan Bělohlávek, Pavel Jansa","doi":"10.1002/pul2.12431","DOIUrl":"10.1002/pul2.12431","url":null,"abstract":"COVID-19 associates with a hypercoagulant state and an increased risk for venous thromboembolic events (VTEs). Whether severe COVID-19 infection requiring extracorporeal membrane oxygenation (ECMO) support might lead to chronic pulmonary perfusion abnormalities and chronic thromboembolic pulmonary disease/hypertension remains unclear. The purpose of this study was to evaluate chronic pulmonary perfusion abnormalities in long-term survivors of COVID-19-related severe acute respiratory distress syndrome (ARDS) treated by ECMO at our institution. Pulmonary perfusion was examined by ventilation/perfusion (V/Q) single-photon emission computed tomography or V/Q planar scintigraphy at least 3 months after ECMO explantation, comorbidities and incidence of thromboembolic events were recorded as well. Of 172 COVID-19 patients treated by ECMO for severe COVID-19 pneumonia between March 2020 and November 2021, only 80 were successfully weaned from ECMO. Of those, 37 patients were enrolled into the present analysis (27% female, mean age 52 years). Median duration of ECMO support was 12 days. In 24 (65%) patients VTE was recorded in the acute phase (23 patients developed ECMO cannula-related deep vein thrombosis, 5 of them had also a pulmonary embolism, and one thrombus was associated with a central catheter). The median duration between ECMO explantation and assessment of pulmonary perfusion was 420 days. No segmental or larger mismatched perfusion defects were then detected in any patient. In conclusion, in long-term survivors of COVID-19-related ARDS treated by ECMO, no persistent pulmonary perfusion abnormalities were detected although VTE was common.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"14 3","pages":"e12431"},"PeriodicalIF":2.2,"publicationDate":"2024-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11345203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Better efficacy of sequential combination with balloon pulmonary angioplasty after long-term riociguat for patients with inoperable chronic thromboembolic pulmonary hypertension. 对无法手术的慢性血栓栓塞性肺动脉高压患者进行长期利奥吉曲特治疗后，序贯联合球囊肺血管成形术的疗效更佳。

IF 2.2 4区医学

Pulmonary Circulation Pub Date : 2024-08-25 eCollection Date: 2024-07-01 DOI: 10.1002/pul2.12429

Wei Wang, Jianfeng Wang, Suqiao Yang, Tuguang Kuang, Yidan Li, Juanni Gong, Yuanhua Yang

{"title":"Better efficacy of sequential combination with balloon pulmonary angioplasty after long-term riociguat for patients with inoperable chronic thromboembolic pulmonary hypertension.","authors":"Wei Wang, Jianfeng Wang, Suqiao Yang, Tuguang Kuang, Yidan Li, Juanni Gong, Yuanhua Yang","doi":"10.1002/pul2.12429","DOIUrl":"10.1002/pul2.12429","url":null,"abstract":"The present study aimed to evaluate the efficacy of long-term riociguat sequentially combined with balloon pulmonary angioplasty (BPA) for patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Eight inoperable CTEPH patients were enrolled in this study, who have been administrated riociguat 2.5 mg three times daily for about 8 years, then underwent several sessions of BPA procedures. Data are prospectively collected to evaluate clinical outcomes, hemodynamics, exercise capacity, and right heart size and function by echocardiography at baseline, 8 years after riociguat, and 3 months after the final BPA. Eight patients (mean age 54.9 ± 11.4 years) were treated with riociguat 2.5 mg three times daily for 95.0 ± 10.7 months. Cardiac index (CI) (1.5 ± 0.5 L/min/m2 to 2.4 ± 0.6 L/min/m2, p = 0.005), 6 min walking distance (6MWD) (329.6 ± 87.5 m to 418.1 ± 75.8 m, p = 0.016), and pulmonary vascular resistance (PVR) (1336.9 ± 320.2 dyn·s·cm-5 to 815.4 ± 195.6 dyn·s·cm-5, p = 0.008) were significant improvement after riociguat treatment. Mean 4.1 ± 1.6 additional combinational BPA sessions and mean 18.8 ± 8.1 balloon dilations were performed. Mean pulmonary artery pressure (54.1 ± 11.1 mmHg to 33.6 ± 7.7 mmHg, p = 0.002) and PVR (815.4 ± 195.6 dyn·s·cm-5 to 428.3 ± 151.2 dyn·s·cm-5, p＜0.001) were further decreased. CI (2.4 ± 0.6 L/min/m2 to 2.7 ± 0.7 L/min/m2, p = 0.028) and 6MWD (418.1 ± 75.8 m to 455.7 ± 100.0 m, p = 0.038) were increased significantly. After long-term riociguat treatment, sequential combination with BPA delivered considerably incremental benefits on exercise capacity and pulmonary hemodynamics, as well as right heart size and function of technically inoperable CTEPH patients.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"14 3","pages":"e12429"},"PeriodicalIF":2.2,"publicationDate":"2024-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11345204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inoperable chronic thromboembolic pulmonary hypertension: Evolution of prognosis over 10 years of new emerging therapies. 无法手术的慢性血栓栓塞性肺动脉高压：新兴疗法十年来的预后演变。

IF 2.2 4区医学

Pulmonary Circulation Pub Date : 2024-08-22 eCollection Date: 2024-07-01 DOI: 10.1002/pul2.12419

Diederik P Staal, Paul M Hendriks, Mitch C J van Thor, Liza D van de Groep, Leon M van den Toorn, Berend-Jan M Mulder, Prewesh P Chandoesing, Robert M Kauling, Sanne Boerman, Annemien E van den Bosch, Johannes J Mager, Karin A Boomars, Martijn C Post

引用次数: 0

Novel evaluation of pulmonary hypertension associated with chronic lung disease using perfusion SPECT/CT: A pilot study. 利用灌注 SPECT/CT 对与慢性肺病相关的肺动脉高压进行新评估：一项试点研究。

IF 2.2 4区医学

Pulmonary Circulation Pub Date : 2024-08-21 eCollection Date: 2024-07-01 DOI: 10.1002/pul2.12423

Kenichiro Atsumi, Yoshimitsu Fukushima, Yosuke Tanaka, Shunichi Nishima, Toru Tanaka, Masahiro Seike, Yoshiaki Kubota, Hiroshi Kimura

{"title":"Novel evaluation of pulmonary hypertension associated with chronic lung disease using perfusion SPECT/CT: A pilot study.","authors":"Kenichiro Atsumi, Yoshimitsu Fukushima, Yosuke Tanaka, Shunichi Nishima, Toru Tanaka, Masahiro Seike, Yoshiaki Kubota, Hiroshi Kimura","doi":"10.1002/pul2.12423","DOIUrl":"10.1002/pul2.12423","url":null,"abstract":"In pulmonary hypertension (PH) associated with chronic lung disease (CLD), identifying patients who would benefit from pulmonary vasodilators is a significant clinical challenge because the presence of PH is associated with poorer survival. This study evaluated the severity of pulmonary circulation impairment in patients with CLD-PH using pulmonary perfusion single-photon emission computed tomography/computed tomography (SPECT/CT). This single-center, observational study enrolled patients with CLD-PH who had a mean pulmonary arterial pressure (PAP) ≥ 25 mmHg, as confirmed by right heart catheterization. The primary outcome was to measure the percentage of pulmonary perfusion defect (%PPD), calculated by dividing the perfusion defect volume from perfusion SPECT images by the lung volume from CT scan images. The secondary outcome was to assess the correlation between %PPD and baseline characteristics. The median %PPD was 52.4% (interquartile range, 42.5%-72.3%) in 22 patients. In multivariate linear regression analysis, both forced vital capacity (β = 0.58, p = 0.008) and mean PAP (β = 0.68, p = 0.001) were significantly correlated with %PPD. In conclusion, significant correlation between mean PAP and %PPD in patients with CLD-PH was observed. This noninvasive assessment of %PPD may be useful for evaluating the severity of pulmonary circulation impairment in CLD-PH.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"14 3","pages":"e12423"},"PeriodicalIF":2.2,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11337537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial on "Characteristics and risk profiles of patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension living permanently at >2500 m of high altitude in Ecuador". 关于 "长期生活在海拔超过 2500 米的厄瓜多尔高海拔地区的肺动脉高压或慢性血栓栓塞性肺动脉高压患者的特征和风险概况 "的社论。

IF 2.2 4区医学

Pulmonary Circulation Pub Date : 2024-08-19 eCollection Date: 2024-07-01 DOI: 10.1002/pul2.12428

Samantha Sharma, Naresh Singh

引用次数: 0

Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension. selexipag维持剂量对美国肺动脉高压患者坚持治疗、依从性和住院治疗的影响。

IF 2.2 4区医学

Pulmonary Circulation Pub Date : 2024-08-18 eCollection Date: 2024-07-01 DOI: 10.1002/pul2.12415

Charles D Burger, Wenze Tang, Yuen Tsang, Sumeet Panjabi

{"title":"Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension.","authors":"Charles D Burger, Wenze Tang, Yuen Tsang, Sumeet Panjabi","doi":"10.1002/pul2.12415","DOIUrl":"10.1002/pul2.12415","url":null,"abstract":"Selexipag is an oral selective agonist of the prostacyclin receptor approved to treat adults with pulmonary arterial hypertension (PAH). Selexipag is initiated at a dose of 200 μg twice daily (bid) and usually titrated up by 200 μg bid weekly (per label) or more slowly (e.g., every other week in real-world clinical practice) to the highest tolerated individualized dose (ID) ranging from 200 to 1600 µg bid. In the Phase 3 GRIPHON trial, selexipag delayed disease progression and reduced risk of PAH-related hospitalization compared with placebo; the effect was consistent across three prespecified ID groups: low (200-400 µg bid), medium (600-1000 µg bid), and high (1200-1600 µg bid). This study evaluated patient outcomes across selexipag dose ranges in real-world practice. Data were analyzed from 1186 US adult patients with PAH on selexipag from the Komodo closed-claims database (2015‒2022). Of these, 634 (53.5%) patients completed titration and reached their selexipag ID (43.8% high ID, 29.8% medium ID, 26.3% low ID). Subsequently, 72.4% of patients in the low ID group had dose adjustments compared with 61.9% (medium ID) and 34.5% (high ID; standardized mean difference 0.63). There were no significant differences in patient outcomes, i,e, persistence (time to discontinuation) and risk of all-cause and PAH-related hospitalization across ID groups. The findings in this diverse, real-world population of patients with PAH reinforced an individualized approach to the dosing scheme to maximize benefit-risk and achieve the highest tolerated dose with selexipag similar to findings from the GRIPHON trial and other studies.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"14 3","pages":"e12415"},"PeriodicalIF":2.2,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11330629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Carnitine consumption and effect of oral supplementation in human pulmonary arterial hypertension: A pilot study. 肉碱消耗量和口服补充剂对人体肺动脉高压的影响：一项试点研究。

IF 2.2 4区医学

Pulmonary Circulation Pub Date : 2024-08-15 eCollection Date: 2024-07-01 DOI: 10.1002/pul2.12425

Evan L Brittain, Alisha Lindsey, Kelly Burke, Vineet Agrawal, Ivan Robbins, Meredith Pugh, M Wade Calcutt, Ravi Mallugari, James West, Hui Nian, Anna R Hemnes

引用次数: 0